Shilpa Medicare’s 100% subsidiary--Shilpa Pharma Lifesciences has received GMP Certification from COFEPRIS-Mexico for its Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state. The said manufacturing facility had undergone a GMP inspection by COFEPRIS-Mexico from November 6, 2023 to November 10, 2023.
The facility is involved in manufacturing various oncology and nononcology APIs. The company remains commit ted to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
